IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., developer of miniaturized implantable Sacral Neuromodulation technology, announced today that it has completed a $38.5 million ...
A novel sacral neuromodulation system (SNM; SacralStim), which has an electrode with six contact points (CPs), shows benefit in the treatment of refractory overactive bladder (OAB), according to a ...
SAN JOSE, Calif., Feb. 10, 2026 /PRNewswire/ -- Neuspera® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced a milestone patient ...
Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option. Investigators from the University of Rome Tor ...
Axonics Modulation Technologies (AXNX) intends to raise $100 million from the sale of its common stock in an IPO, per an amended registration statement. The company is developing a sacral ...
The company is hoping to gain FDA approval for its SNM device. (Axonics) Axonics Modulation Technologies has pulled in a meaty IPO as it looks to compete with medical technology major Medtronic for ...
ARTISAN‑SNM (McCrery 2019 and Lane 2020; n=129 patients), which included 19 centres in the US and Europe (the Netherlands, Belgium, France and the UK) and had a follow up of 12 months. RELAX‑OAB (Blok ...
IRVINE, Calif. — Axonics Modulation Technologies, Inc., (NASDAQ: AXNX), developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results